Integra LifeSciences (NASDAQ:IART) Lowered to Equal Weight at Wells Fargo & Company

Wells Fargo & Company lowered shares of Integra LifeSciences (NASDAQ:IART) from an overweight rating to an equal weight rating in a research note released on Tuesday morning, Marketbeat.com reports. The firm currently has $25.00 target price on the life sciences company’s stock, down from their prior target price of $45.00.

Other analysts also recently issued research reports about the stock. JMP Securities reduced their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating for the company in a research report on Thursday, February 29th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a hold rating for the company in a report on Friday, March 1st. StockNews.com lowered shares of Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Finally, Citigroup upgraded Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price target for the company in a research note on Wednesday, April 3rd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of Hold and an average target price of $36.80.

Integra LifeSciences Trading Up 8.4 %

NASDAQ:IART opened at $25.08 on Tuesday. The firm has a fifty day simple moving average of $32.95 and a two-hundred day simple moving average of $38.24. Integra LifeSciences has a 12 month low of $22.36 and a 12 month high of $51.12. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. The business had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.74 EPS. Analysts expect that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently bought and sold shares of the business. Signaturefd LLC increased its position in shares of Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Hexagon Capital Partners LLC increased its holdings in Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after buying an additional 370 shares during the last quarter. Gladius Capital Management LP bought a new stake in Integra LifeSciences in the third quarter worth about $47,000. Valley National Advisers Inc. purchased a new position in Integra LifeSciences in the first quarter valued at about $63,000. Finally, Covestor Ltd grew its position in shares of Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 921 shares during the period. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.